Multimodal Imaging Analysis During Treatment With Bevacizumab in Patients With Recurrent Glioblastoma
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the capacity of the multimodal imaging parameters
measured at 15 days and 2 months of initiation of treatment with bevacizumab, to measure
changes in clinical status (sensitivity to measure changes) in patients treated for recurrent
glioblastoma.